The central bank is not normally in the business of easing into an economy that is showing few signs of a recession, generally holding fire until more pronounced signs of a...The Fedread more
His case for gold comes as central banks get more aggressive with policies that devalue currencies and are about to cause a "paradigm shift" in investing.Marketsread more
CSX said it expects revenue to fall as much as 2% in 2019, well below a previous forecast of an increase of 1% to 2%.Marketsread more
Challenging conditions in the U.S. housing market, along with tighter currency controls by the Chinese government, cause a stunning drop in foreign demand for American homes.Real Estateread more
The growth in net interest income, a main engine of the industry's profit, looks to slow to a halt in the back half of this year.Banksread more
Here's how Amazon sells ads, and why it has a natural edge over Google and Facebook in some areas.Technologyread more
Netflix reports earnings Wednesday as it loses licensed shows to rivals launching their own streaming services.Technologyread more
Federal Judge William Pauley wrote in a court filing made public Wednesday that materials related to Cohen's campaign-finance probe should be unsealed — and denied a request...Politicsread more
The "'Cadillac tax," set to go into effect in 2022, is unpopular with both Republicans and Democrats, who say it punishes the middle class.Health and Scienceread more
Facebook's head of Calibra David Marcus is grilled during a House Financial Services Committee hearing over the company's digital currency plans.Technologyread more
Gov. Phil Murphy of New Jersey announced a lawsuit against the IRS and Treasury Secretary Steven Mnuchin, responding to new, final rules from the IRS that would largely block...Personal Financeread more
Eli Lilly has been on a roller coaster in the wake of patent expirations, Chairman and CEO John Lechleiter told CNBC on Friday after the drugmaker reported a 41 percent fall in quarterly profit.
Lilly was hurt by a stronger dollar and a one-time charge related to a restructuring program.
The company said it earned $428.5 million, or 40 cents per share, in the fourth quarter ended Dec. 31 from $727.5 million, or 67 cents per share, a year earlier. Its stock price was up slightly in premarket trading Friday. (Click here for the latest price.)
"It's been up and down. As you know when you lose a patent in this business the generic entry comes very quickly and you essentially lose all of that revenue overnight," Lechleiter said in a "Squawk Box" interview.
To deal with the bleed, the company has been investing in research and development and replenishing its pipeline of drugs, he said. He noted that Lilly received approval for four new products from the Food and Drug Administration in the past year.
With more than half of its sales generated outside the United States, the strengthening dollar impacted sales significantly, Lechleiter said. The company, however, did not change its full-year earnings guidance of $3.10 to $3.20 per share on a non-GAAP basis.
"Even though our revenues are coming down from those sales and countries that have weakened currencies versus the dollar, we actually gain a benefit from the cost of our inventories that sit outside the United States, so our gross margin actually increases, and that tends to balance things out."
The company's earnings have been battered over the past three years due to patent expirations on its biggest medicines.
—Reuters contributed to this report.